Literature DB >> 1396956

Inhibition of human immunodeficiency virus infection in human colon epithelial cells by recombinant interferon-gamma.

N Yahi1, S Baghdiguian, C Bolmont, J Fantini.   

Abstract

Pretreatment of human colon epithelial cells HT29 by recombinant gamma interferon (IFN)-gamma was found to protect the cells from infection with various isolates of human immunodeficiency virus (HIV)-1 and HIV-2, as assessed by co-cultivation with human T lymphoblastoid cells and gene amplification by polymerase chain reaction technique. Additionally, IFN-gamma induced a dose-dependent inhibition of HIV-1 and HIV-2 production in chronically infected HT29 cells. In situ hybridization studies demonstrated that IFN-treated cells were still able to synthesize viral messenger ribonucleic acid. However, the expression of the p24 product of the gag gene was markedly decreased after IFN treatment as demonstrated by radio-immunoprecipitation assay. Taken together, these data suggested that the cytokine acted at the post-translational level by inhibiting the processing of structural viral proteins. It is concluded from this study that IFN-gamma has a potent anti-HIV effect on epithelial gastrointestinal cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396956     DOI: 10.1002/eji.1830221005

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Production of a highly cytopathic HIV-1 isolate from a human mucosal epithelial cell line cultured on microcarrier beads in serum-free medium.

Authors:  N Yahi; S Baghdiguian; J Fantini
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-01       Impact factor: 2.416

2.  P. falciparum enhances HIV replication in an experimental malaria challenge system.

Authors:  Marika Orlov; Florin Vaida; Olivia C Finney; David M Smith; Angela K Talley; Ruobing Wang; Stefan H Kappe; Qianqian Deng; Robert T Schooley; Patrick E Duffy
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.